TB Clip 2022년 7월호 본문 이미지

편집자 한마디!

국내외 결핵(TB)뉴스

학술연구자료

STOP - TB 코리아 소식

안녕하세요. 6월말에 메일로 한국OIAA (오츠카의 아시아 region office)의 청산으로 저의 퇴직을 알렸습니다만, Monthly TB Clips는 Stop TB Partnership의 협조로 계속 송부될 예정입니다.
저의 메일 주소가 smileha4u@gmail.com 로 바뀐 점 확인 부탁드리며, 앞으로도 많은 지도편달 부탁드리겠습니다. 감사합니다.

The World Health Organization (WHO) released updated guidelines and a new operational handbook on TB care and support to improve the quality of life and better outcomes for people with TB. This includes for the first-time implementation guidance on health education, counseling and palliative care as well as on social support, treatment administration options and digital adherence technologies

The World Health Organization (WHO) Global TB Program launched a call for submissions of best practices on the engagement of affected communities and civil society to accelerate progress to end TB. Civil society and affected communities, representatives of national TB programs, partners, and other stakeholders at the sub-national, national and regional levels are invited to submit examples of relevant best practices. Full details about the call are available here. The submission deadline is 15 August 2022.

The World Health Organization releases the first-ever report on the pipeline of the vaccines currently in development to prevent infections caused by antimicrobial-resistant bacterial pathogens. The analysis identifies sixty-one vaccine candidates in various stages of clinical development, including several in late stages of development to address diseases listed on the bacterial priority pathogens list, which WHO has prioritized for R&D. While the report describes these late-stage vaccine candidates as having a high development feasibility, the report cautions that most will not be available anytime soon. The full report can be read here.

The Stop TB Partnership launched the Global Plan to End TB 2023-2030 outlining the priority actions and estimating financial resources needed to end TB as a global health threat by 2030. Between 2023 and 2030, the Global Plan calls for the mobilization of US$249.98 billion: US$157.2 billion for TB prevention and care, US$52.6 billion for vaccination once new vaccines are available, and an additional US$40.18 billion to accelerate the development of new TB medicines, treatment regimens and diagnostics.

Community Connect is a valuable addition and important highlight of the Union World Conference on Lung Health 2022 which will take place virtually on 8-11 November 2022. Session submissions deadline has been extended to 8 July 2022 (creative session submissions close on 15 August). For further details, click here. TB survivors and the affected lung health community are provided sponsored registrations to the conference. All details are available here.

The World Health Organization’s Global TB Program is seeking expressions of interest from academic institutions or other entities with relevant expertise and experience to conduct systematic reviews of the published data on the relative risks of health-related risk factors that drive the TB epidemic globally. For full details about the call, click here. The deadline for submissions is by close of business on 12 August 2022.

The University of Oxford has begun recruiting for a Phase I trial with a TB vaccine in human volunteers to develop a new way to test the efficacy of future TB vaccines. Source: University of Oxford

The National Institute for Research in TB at the Indian Council of Medical Research (ICMR) has initiated a study to assess the efficacy of a four-month TB treatment regimen for drug-susceptible TB as compared to the existing six-month regimen.Source: ThePrint

The National Institute for Research in TB at the Indian Council of Medical Research (ICMR) plans to initiate a study to demonstrate the effect of Bacille Calmette-Guérin (BCG) revaccination in comparison to oral chemoprophylaxis on the incidence of Mycobacterium tuberculosis disease in healthy household contacts, aged 6-18 years. Source: Mint

Tuberculosis is one of the leading causes of death for people with HIV. HIV damages patients’ immune system and makes them more vulnerable to contracting serious bacterial infections such as TB.Source: Healthline

The use of nanopore sequencing for the early identification of pulmonary TB infection had superior diagnostic accuracy compared with both Mycobacterium tuberculosis culture analyses and Xpert MTB/rifampin assays, according to results of a study published in International Journal of Infectious Diseases.

In February, the U.S. Centers for Disease Control and Prevention (CDC) published new interim guidance on a 4-month treatment regimen as an option for the U.S. patients with drug-susceptible pulmonary TB, consisting of high-dose daily rifapentine with moxifloxacin, isoniazid, and pyrazinamide. А commentary in Medscape presents 5 important things about the regimen.

According to study results, published in Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, moxifloxacin, when used as part of a shorter treatment regimen for drug-resistant TB, appears not to increase the risk for prolonging the QT interval.

According to study results, published in Therapies, patients with diabetes mellitus (DM) and TB had a significantly higher incidence of low rifampicin plasma levels two hours after the drug was administered, compared with patients with TB who did not have DM.

Researchers investigated whether data collected as part of routine, national TB surveillance could be used to develop predictive models to identify additional resistance to fluoroquinolones at the time of diagnosis with rifampin-resistant TB.

A study, published in Science, highlighted the reverse electron transport pathway’s role as a major pathogenic mechanism of TB. Reverse electron transport causes overproduction of mitochondrial reactive oxygen species, a key contributor to the aggravation of TB pathogenesis.

RESIST-TB released its June 2022 newsletter with the latest research publications on drug-resistant TB.

The International Union Against Tuberculosis and Lung Disease released the July 2022 issue of the International Journal of Tuberculosis and Lung Disease (IJTLD). It includes TB-related research publications.